Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
OBRIEN JAMES J /KY reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director James J. O'Brien received a grant of 1,628 shares of common stock as a restricted stock award. The award was granted at no cash cost and represents his annual Restricted Stock Award. After this grant, he holds 8,456 shares directly.
The restricted shares are scheduled to lapse on May 7, 2027, subject to conditions tied to his continued service as a director. In addition to his direct holdings, he also indirectly owns 1,022 shares through a revocable trust.
BUTLER ERIC L reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Eric L. Butler received a grant of 1,628 shares of common stock as a restricted stock award. The shares were awarded at no cash cost per share and represent his annual Restricted Stock Award as a director. Following this grant, Butler directly holds 10,958 shares of Eastman Chemical common stock. The restrictions on these shares will lapse on May 7, 2027, subject to conditions tied to his continued service as a director.
Eastman Chemical Company director Linnie M. Haynesworth received an annual equity grant in the form of restricted common shares. On May 7, 2026, she acquired 1,628 shares at no cash price as a grant or award, increasing her direct holdings to 3,135 shares. These are restricted shares, with restrictions scheduled to lapse on May 7, 2027, subject to conditions related to her continued service as a director. The share amount represents her annual Restricted Stock Award, reflecting routine director compensation rather than an open-market purchase or sale.
Audia Damon J reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Damon J. Audia reported a compensation-related grant of 1,628 Phantom Stock Units on May 7, 2026. These units, each valued at $73.69, are credited under the Directors' Deferred Compensation Plan and bring his total phantom units to 4,274.
The units will vest on May 7, 2027 and are payable only in cash, not stock. According to the footnotes, this represents a deferral of the value of his annual non-employee director restricted stock award that otherwise would have been paid in common shares, making this a routine, non-market transaction.
Eastman Chemical Company senior vice president Adrian James Holt reported selling common stock and settling deferred compensation units. On May 5, 2026, he executed an open-market sale of 1,709 shares of common stock at $77.05 per share, leaving no directly held shares from this position in the filing. The same day, he disposed of 2,271 Phantom Stock Units to the issuer under an Executive Deferred Compensation Plan, each unit valued based on the closing price of Eastman Chemical common stock on the disposition date, also leaving no remaining units from this grant.
Eastman Chemical Company reported weaker results for the first quarter of 2026. Sales decreased 5% to $2,177 million from $2,290 million a year earlier, as lower volumes and prices, especially in Chemical Intermediates and Fibers, outweighed modest foreign-exchange benefits.
Net earnings attributable to Eastman fell to $107 million from $182 million, and diluted EPS declined to $0.93 from $1.57. On an adjusted basis, excluding restructuring and tax items, EPS was $1.09 versus $1.91. Gross profit dropped to $431 million from $567 million, reflecting weaker pricing, demand and lower asset utilization.
By segment, Adjusted EBIT declined sharply in Advanced Materials and Fibers, while Additives & Functional Products held roughly flat and Chemical Intermediates swung to a loss. The company recognized a $22 million benefit from expected refunds of invalidated IEEPA tariffs, partially offsetting Winter Storm–driven energy costs.
Operating cash flow was a use of $137 million, similar to the prior-year outflow, largely due to working capital swings. Eastman issued $600 million of 4.5% notes due 2031 (net proceeds $594 million) and repaid the remaining $150 million on a 2027 term loan, ending the quarter with $665 million in cash and total borrowings of $5,220 million.
Eastman Chemical Company reported first-quarter 2026 results with sales revenue of $2,177 million, down 5% from $2,290 million a year earlier, and diluted EPS of $0.93 versus $1.57. Adjusted EBIT was $200 million compared with $311 million, and adjusted EPS was $1.09 versus $1.91.
EBIT fell to $188 million from $302 million, driven by weaker spreads in Chemical Intermediates, lower volume in Fibers, lower asset utilization in Advanced Materials, and higher energy costs, partially offset by cost reductions and an expected tariff refund. Cash used in operating activities improved to $137 million from $167 million as the company built inventory ahead of planned shutdowns and returned $96 million in dividends.
Management is implementing about $500 million of price increases and targeting $125–$150 million of net cost savings in 2026, with capital spending of approximately $400 million. They expect significantly higher 2026 earnings versus 2025 and project second-quarter 2026 adjusted diluted EPS between $1.70 and $1.90, helped by margin improvement in Chemical Intermediates and stronger specialty volume.
Eastman Chemical Co ownership disclosure: Vanguard Capital Management reports beneficial ownership of 5,974,518 shares of Common Stock, representing 5.22% of the class as of 03/31/2026. The filing shows sole dispositive power over 5,974,518 shares and sole voting power for 865,800 shares. The filing was signed on 04/29/2026.
Eastman Chemical Co reported that Vanguard Portfolio Management beneficially owns 7,670,415 shares of Common Stock, equal to 6.7% as of 03/31/2026. The filing shows sole dispositive power for 7,670,415 shares and sole voting power for 42,061 shares. Vanguard states these holdings include securities held for Vanguard funds and managed accounts and are reported on behalf of those clients.